Skip to main content

Information updates

ASCIA Action Plans for Anaphylaxis - 2025 versions

ASCIA Action Plans for Anaphylaxis are emergency response plans for severe allergic reactions (anaphylaxis). 

Major updates were made in the 2023 versions, and only minor updates have been made to the 2025 versions, which are available from mid-November 2024 on the ASCIA website:

www.allergy.org.au/hp/anaphylaxis/ascia-action-plan-for-anaphylaxis 

www.allergy.org.au/hp/ascia-plans-action-and-treatment 

ASCIA has developed 2025 versions of red ASCIA Action Plans for Anaphylaxis and orange ASCIA First Aid Plans for Anaphylaxis, in response to recent and future changes in adrenaline (epinephrine) devices: 

  • Anapen® 150 and Anapen® 300 are no longer available in Australia, so only Anapen® 500 is listed on the general and Anapen® specific versions of ASCIA Action and First Aid Plans from 2025 onwards.
  • ASCIA resources are being updated by replacing “injector” with “device”, to enable ASCIA resources to remain relevant when other types of adrenaline devices (that are not injectors, such as those recently approved in the US for routine use) become available in Australia and New Zealand.

To ensure consistency, all ASCIA anaphylaxis resources will be updated in 2025 with the changes noted above, including ASCIA anaphylaxis e-training courses, device specific plans for EpiPen® and Anapen®, green ASCIA Action Plans for Allergic Reactions and dark green ASCIA Action Plans for Drug Allergy.

pdfASCIA Action Plan Anaphylaxis 2025 What's New394.55 KB

pdfASCIA First Aid Plan Anaphylaxis 2025 What's New417.12 KB

Prior versions (2023) will still be valid for use in 2025. Information about what was updated in the 2023 plans is available at www.allergy.org.au/about-ascia/info-updates/new-2023-versions-of-ascia-action-plans-for-anaphylaxis  

ASCIA Action Plans do not expire, and therefore the plan is still valid beyond the recommended review date, which is a guide for patients to see their doctor. They are medical documents that are completed (patient details can be typed into text fields at the top) and signed by the treating doctor or nurse practitioner.  

For more information about ASCIA Action Plans go to www.allergy.org.au/hp/anaphylaxis/action-plans-for-allergic-reactions-faq

This news item was issued on 13 November 2024 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.